Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Marie Skłodowska-Curie Action-beurs voor Bernadette van den Hoogen
jul 2019 | Virale infecties